ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2020
Penicillin as a Potential Agent for Dual β-Lactam Therapy for Enterococcal Endocarditis.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 17 citations in OpenAlex.
- Ceftobiprole alone versus ampicillin-ceftriaxone against borderline-penicillin-resistant, ampicillin-susceptible, and vancomycin-resistantAntimicrobial agents and chemotherapy · 2026Article
- Dual β-lactam synergy in Enterococcus faecalis and its relationship with penicillin-ceftriaxone infective endocarditis treatment outcomes.The Journal of antimicrobial chemotherapy · 2025Article
- Comparison of ceftriaxone versus ceftaroline in combination with ampicillin or penicillin againstMicrobiology spectrum · 2025Article
- Treatment of infective endocarditis caused byFrontiers in cardiovascular medicine · 2025Article
- The emerging challenge ofClinical microbiology reviews · 2024Review
- Outpatient parenteral antimicrobial therapy for patients withJAC-antimicrobial resistance · 2024Article
- Penicillin-Binding Proteins and Alternative Dual-Beta-Lactam Combinations for Serious Enterococcus faecalis Infections with Elevated Penicillin MICs.Antimicrobial agents and chemotherapy · 2023Article
- A retrospective study ofJAC-antimicrobial resistance · 2022Article
- Penicillin plus Ceftriaxone versus Ampicillin plus Ceftriaxone Synergistic Potential against Clinical Enterococcus faecalis Blood Isolates.Microbiology spectrum · 2022Article
- Infectious disease: how to manage Gram-positive and Gram-negative pathogen conundrums with dual beta-lactam therapy.Drugs in context · 2022Review
- In Vitro Synergism of Penicillin and Ceftriaxone againstMicroorganisms · 2021Article
- Ampicillin Plus Ceftriaxone Regimen againstJournal of clinical medicine · 2021Review
- A clinical andJAC-antimicrobial resistance · 2021Article
- Review
Corrections and comments
- Comment on
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.